• 14. Cash and cash equivalents
• 15. Trade accounts receivable
• 16. Inventories
• 17. Other current and non-current assets
• 18. Property, plant and equipment
• 19. Goodwill and other intangible assets
• 20. Accrued expenses
• 21. Other liabilities
• 22. Debt and capital lease obligations
• 23. Senior Notes
• 24. Mandatory Exchangeable Bonds
• 25. Trust preferred securities
• 26. Pensions and similar obligations
• 27. Noncontrolling interest
• 28. Fresenius SE & Co. KGaA shareholders’ equity
• 29. Other comprehensive income (loss)

17. Other current and non-current assets

As of December 31, other current and non-current assets comprised the following:

As of December 31, 2012, investments, securities and long-term loans comprised investments of €484 million (2011: €537 million), mainly regarding the joint venture between Fresenius Medical Care and Galenica Ltd., that were accounted for under the equity method. In 2012, income of €14 million (2011: €22 million) resulting from this valuation was included in selling, general and administrative expenses in the consolidated statement of income. Moreover, investments, securities and long-term loans included €182 million financial assets available for sale as of December 2012 (2011: €26 million). Furthermore, investments, securities and long-term loans comprised €181 million as of December 31, 2011 that Fresenius Medical Care loaned to Renal Advantage Partners, LLC.

The receivables resulting from the German hospital law primarily contain approved but not yet received earmarked subsidies of the Fresenius Helios operations. The approval is evidenced in a letter written by the granting authorities that Fresenius Helios has already received.

Depreciation on other non-current assets in an amount of €2 million was recognized in the fiscal year 2012 (2011: depreciation in an immaterial amount).